Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes

Cancer

Volumn 120, Issue 11, 2014, Pages 1670-1676

  Steensma, David P ^a   Komrokji, Rami S ^b   Stone, Richard M ^a   List, Alan F ^b   Garcia Manero, Guillermo ^c   Huber, John M ^d   Dennison, Betsy ^e   Sekeres, Mikkael A ^f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Aplastic Anemia and MDS International Foundation   (United States)

^e Clarity Communications ^*  (United States)

^f TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

azacitidine; communication; decitabine; lenalidomide; myelodysplastic syndromes; therapy adherence

Indexed keywords

ADULT; ARTICLE; ATTITUDE TO ILLNESS; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERCEPTION; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; TREATMENT PLANNING; TREATMENT RESPONSE;

AZACITIDINE; COMMUNICATION; DECITABINE; LENALIDOMIDE; MYELODYSPLASTIC SYNDROMES; THERAPY ADHERENCE;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATIENT EDUCATION AS TOPIC; PERCEPTION; PHYSICIANS; TREATMENT OUTCOME;

EID: 84901316927     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28631     Document Type: Article

References (23)

1. Steensma DP, Bennett JM,. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006; 81: 104-130.
2. Goldberg SL, Chen E, Sasane M, Paley C, Guo A, Laouri M,. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion. 2012; 52: 2131-2138.
3. Steensma DP, Heptinstall KV, Johnson VM, et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res. 2008; 32: 691-698.
4. Ma X, Does M, Raza A, Mayne ST,. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007; 109: 1536-1542.
5. Cogle CR, Craig BM, Rollison DE, List AF,. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011; 117: 7121-7125.
6. Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010; 116: 2174-2179.
7. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007; 109: 1705-1714.
8. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of 6 cross-sectional physician surveys. J Natl Cancer Inst. 2008; 100: 1542-1551.
9. Deeg HJ, de Lima M,. Hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. J Natl Compr Canc Netw. 2013; 11: 1227-1233.
10. Sekeres MA, Maciejewski JP, List AF, et al. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist. 2011; 16: 904-911.
11. Smith BD,. Myelodysplastic syndromes: challenges to improving patient and caregiver satisfaction. Am J Med. 2012; 125 (7 suppl): S26-S30.
12. Kurtin SE, Paterson P, Wintrich S, et al. Patient and family resources for living with myelodysplastic syndromes. Clin J Oncol Nurs. 2012; 16 (suppl): 58-64.
13. Voso MT, Breccia M, Lunghi M, et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol. 2013; 90: 345-348.
14. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011; 117: 2697-2702.
15. Greenberg PL, Attar E, Bennett JM, et al. Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2013; 11: 838-874.
16. Hahn T, McCarthy PL, Jr, Hassebroek A, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013; 31: 2437-2449.
17. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120: 2454-2465.
18. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20: 2429-2440.
19. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106: 1794-1803.
20. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355: 1456-1465.
21. Sekeres MA, Maciejewski JP, Donley DW, et al. A study comparing dosing regimens and efficacy of subcutaneous to intravenous azacitidine (AZA) for the treatment of myelodysplastic syndromes (MDS) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 3797.
22. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
23. Steensma DP,. Are myelodysplastic syndromes "cancer?" Unexpected adverse consequences of linguistic ambiguity. Leuk Res. 2006; 30: 1227-1233.